Marisol Salgado-Albarrán

Marisol Salgado-Albarrán

Auto-generated profile, based on publicly available information

Marisol Salgado-Albarrán

Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana-Cuajimalpa (UAM-C), Mexico City 05348, Mexico

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Nature Computational Science
Verified
Journal Article
Closed access
PDF file
GGGihanna Galindez
Gihanna Galindez
JMJulian Matschinske
Julian Matschinske
TRTim Daniel Rose
Tim Daniel Rose
SSSepideh Sadegh
Sepideh Sadegh
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
Josch K. PaulingJosch K. Pauling
Josch K. Pauling

2 April 2019 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
IPIsidro X. Perez‐Añorve
Isidro X. Perez‐Añorve
Claudia Haydée González De La RosaClaudia Haydée González De La Rosa
Claudia Haydée González De La Rosa
ESErnesto Soto-Reyes
Ernesto Soto-Reyes
FBFredy Omar Beltran-anaya
Fredy Omar Beltran-anaya
OMOscar Del Moral‐Hernandez
Oscar Del Moral‐Hernandez
EAElena Arechaga‐Ocampo
Elena Arechaga‐Ocampo
Radioresistance of tumor cells gives rise to local recurrence and disease progression in many patients. MicroRNAs (miRNAs) are master regulators of gene expression that control oncogenic pathways to modulate the radiotherapy response of cells. In the present study, differential expression profiling assays identified 16 deregulated miRNAs in acquired radioresistant breast cancer cells, of which miR‐122 was observed to be up‐regulated. Functional analysis revealed that miR‐122 has a role as a tumor suppressor in parental cells by decreasing survival and promoting radiosensitivity. However, in radioresistant cells, miR‐122 functions as an oncomiR by promoting survival. The transcriptomic landscape resulting from knockdown of miR‐122 in radioresistant cells showed modulation of the ZNF611, ZNF304, RIPK1, HRAS, DUSP8 and TNFRSF21 genes. Moreover, miR‐122 and the set of affected genes were prognostic factors in breast cancer patients treated with radiotherapy. Our data indicate that up‐regulation of miR‐122 promotes cell survival in acquired radioresistant breast cancer and also suggest that miR‐122 differentially controls the response to radiotherapy by a dual function as a tumor suppressor an and oncomiR dependent on cell phenotype.

24 May 2021 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
ENErick I. Navarro-Delgado
Erick I. Navarro-Delgado
AMAylin Del Moral
Aylin Del Moral
NANicolás Alcaraz
Nicolás Alcaraz
Jan BaumbachJan Baumbach
Jan Baumbach
ESErnesto Soto-Reyes
Ernesto Soto-Reyes
COVID-19 is an infection caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), which has caused a global outbreak. Current research efforts are focused on the understanding of the molecular mechanisms involved in SARS-CoV-2 infection in order to propose drug-based therapeutic options. Transcriptional changes due to epigenetic regulation are key host cell responses to viral infection and have been studied in SARS-CoV and MERS-CoV; however, such changes are not fully described for SARS-CoV-2. In this study, we analyzed multiple transcriptomes obtained from cell lines infected with MERS-CoV, SARS-CoV, and SARS-CoV-2, and from COVID-19 patient-derived samples. Using integrative analyses of gene co-expression networks and de-novo pathway enrichment, we characterize different gene modules and protein pathways enriched with Transcription Factors or Epifactors relevant for SARS-CoV-2 infection. We identified EP300, MOV10, RELA, and TRIM25 as top candidates, and more than 60 additional proteins involved in the epigenetic response during viral infection that has therapeutic potential. Our results show that targeting the epigenetic machinery could be a feasible alternative to treat COVID-19.

10 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
AMAylin Del Moral
Aylin Del Moral
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
YSYesennia Sánchez-Pérez
Yesennia Sánchez-Pérez
NWNina Kerstin Wenke
Nina Kerstin Wenke
Jan BaumbachJan Baumbach
Jan Baumbach
ESErnesto Soto-Reyes
Ernesto Soto-Reyes
Architectural proteins are essential epigenetic regulators that play a critical role in organizing chromatin and controlling gene expression. CTCF (CCCTC-binding factor) is a key architectural protein responsible for maintaining the intricate 3D structure of chromatin. Because of its multivalent properties and plasticity to bind various sequences, CTCF is similar to a Swiss knife for genome organization. Despite the importance of this protein, its mechanisms of action are not fully elucidated. It has been hypothesized that its versatility is achieved through interaction with multiple partners, forming a complex network that regulates chromatin folding within the nucleus. In this review, we delve into CTCF’s interactions with other molecules involved in epigenetic processes, particularly histone and DNA demethylases, as well as several long non-coding RNAs (lncRNAs) that are able to recruit CTCF. Our review highlights the importance of CTCF partners to shed light on chromatin regulation and pave the way for future exploration of the mechanisms that enable the finely-tuned role of CTCF as a master regulator of chromatin.

12 August 2019 in Oncogenesis
Verified
Journal Article
Open access
PDF file
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
RGRodrigo González-Barrios
Rodrigo González-Barrios
LGLissania Guerra-Calderas
Lissania Guerra-Calderas
NANicolás Alcaraz
Nicolás Alcaraz
TSThalía Estefanía Sánchez-Correa
Thalía Estefanía Sánchez-Correa
ESErnesto Soto-Reyes
Ernesto Soto-Reyes
The identification of prognostic biomarkers is a priority for patients suffering from high-grade serous ovarian cancer (SOC), which accounts for >70% of ovarian cancer (OC) deaths. Meanwhile, borderline ovarian cancer (BOC) is a low malignancy tumor and usually patients undergo surgery with low probabilities of recurrence. However, SOC remains the most lethal neoplasm due to the lack of biomarkers for early diagnosis and prognosis. In this regard, BORIS (CTCFL), a CTCF paralog, is a promising cancer biomarker that is overexpressed and controls transcription in several cancer types, mainly in OC. Studies suggest that BORIS has an important function in OC by altering gene expression, but the effect and extent to which BORIS influences transcription in OC from a genome-wide perspective is unclear. Here, we sought to identify BORIS target genes in an OC cell line (OVCAR3) with potential biomarker use in OC tumor samples. To achieve this, we performed in vitro knockout and knockdown experiments of BORIS in OVCAR3 cell line followed by expression microarrays and bioinformatics network enrichment analysis to identify relevant BORIS target genes. In addition, ex vivo expression data analysis of 373 ovarian cancer patients were evaluated to identify the expression patterns of BORIS target genes. In vitro, we uncovered 130 differentially expressed genes and obtained the BORIS-associated regulatory network, in which the androgen receptor (AR) acts as a major transcription factor. Also, FN1, FAM129A, and CD97 genes, which are related to chemoresistance and metastases in OC, were identified. In SOC patients, we observed that malignancy is associated with high levels of BORIS expression while BOC patients show lower levels. Our study suggests that BORIS acts as a main regulator, and has the potential to be used as a prognostic biomarker and to yield novel drug targets among the genes BORIS controls in SOC patients.

30 March 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
LGLissania Guerra-Calderas
Lissania Guerra-Calderas
RGRodrigo González-Barrios
Rodrigo González-Barrios
CMCarlos César Patiño Morales
Carlos César Patiño Morales
NANicolás Alcaraz
Nicolás Alcaraz
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
ESErnesto Soto-Reyes
Ernesto Soto-Reyes
CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines